Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M144,144Revenue (TTM) $M16,380Net Margin (%)31.3Altman Z-Score16.6
Enterprise Value $M144,648EPS (TTM) $2.0Operating Margin %43.6Piotroski F-Score7
P/E(ttm)27.6Beneish M-Score-2.4Pre-tax Margin (%)39.1Higher ROA y-yN
Price/Book25.910-y EBITDA Growth Rate %19.2Quick Ratio0.8Cash flow > EarningsY
Price/Sales8.75-y EBITDA Growth Rate %18.8Current Ratio1.1Lower Leverage y-yY
Price/Free Cash Flow27.4y-y EBITDA Growth Rate %5.1ROA % (ttm)41.2Higher Current Ratio y-yY
Dividend Yield %1.7PEG1.5ROE % (ttm)86.7Less Shares Outstanding y-yY
Payout Ratio %47.0Shares Outstanding M2,600ROIC % (ttm)141Gross Margin Increase y-yY

Gurus Latest Trades with NVO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVOKen Fisher 2016-03-31 Reduce-0.03%$46.58 - $58.08
($53.57)
$ 55.443%Reduce -2.35%11,178,809
NVORuane Cunniff 2016-03-31 Add0.01%$46.58 - $58.08
($53.57)
$ 55.443%Add 19.93%97,525
NVOMario Gabelli 2016-03-31 Add$46.58 - $58.08
($53.57)
$ 55.443%Add 0.24%6,225
NVOKen Fisher 2015-12-31 Reduce-0.02%$52.93 - $58.77
($55.36)
$ 55.440%Reduce -1.76%11,447,413
NVOMario Gabelli 2015-12-31 Add$52.93 - $58.77
($55.38)
$ 55.440%Add 0.65%6,210
NVOKen Fisher 2015-09-30 Reduce-0.07%$52.8 - $60.23
($56.62)
$ 55.44-2%Reduce -5.23%11,652,268
NVORuane Cunniff 2015-09-30 Reduce$52.8 - $60.23
($56.62)
$ 55.44-2%Reduce -0.59%81,320
NVOMario Gabelli 2015-09-30 Reduce$52.8 - $60.23
($56.62)
$ 55.44-2%Reduce -5.73%6,170
NVOKen Fisher 2015-06-30 Reduce-0.04%$53.39 - $58.02
($56.17)
$ 55.44-1%Reduce -2.88%12,295,864
NVOMario Gabelli 2015-06-30 Reduce$53.39 - $58.02
($56.17)
$ 55.44-1%Reduce -2.31%6,545
NVORuane Cunniff 2015-06-30 Reduce$53.39 - $58.02
($56.17)
$ 55.44-1%Reduce -0.30%81,800
NVOKen Fisher 2015-03-31 Reduce-0.03%$41.9 - $54.68
($46.05)
$ 55.4420%Reduce -2.91%12,660,235
NVORuane Cunniff 2015-03-31 Reduce$41.9 - $54.68
($46.05)
$ 55.4420%Reduce -0.17%82,050
NVOMario Gabelli 2015-03-31 Reduce$41.9 - $54.68
($46.05)
$ 55.4420%Reduce -0.30%6,700
NVORuane Cunniff 2014-09-30 Reduce-0.02%$43.9 - $49.03
($46)
$ 55.4421%Reduce -52.87%75,642
NVORuane Cunniff 2014-06-30 Reduce-0.02%$42.28 - $46.52
($44.12)
$ 55.4426%Reduce -33.85%160,492
NVORuane Cunniff 2014-03-31 Reduce-0.01%$36.722 - $48.23
($42.37)
$ 55.4431%Reduce -21.98%242,630
NVORuane Cunniff 2013-12-31 Add0.02%$32.72 - $36.95
($34.88)
$ 55.4459%Add 58.71%310,970
NVOTom Gayner 2013-12-31 Reduce$32.72 - $36.95
($34.88)
$ 55.4459%Reduce -0.23%1,106,000
NVOKen Fisher 2013-12-31 Add$32.72 - $36.95
($34.88)
$ 55.4459%Add 0.29%13,553,935
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVO: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about NVO:

    News about NVO:

    Articles On GuruFocus.com
    Jim Simons' Top Holdings Include VeriSign, Chipotle Dec 15 2015 
    Value Investing in BioPharma Nov 18 2015 
    Jim Simons' Five Most-Heavily Weighted Holdings Oct 21 2015 
    Ken Fisher Reduces Stake in Toyota, Increases Position in Anheuser-Busch Oct 20 2015 
    Jim Simons and Ken Fisher Decrease Exposure on Novo Nordisk A/S Sep 14 2015 
    Nintai Returns: Q2 2015 Jul 01 2015 
    Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
    Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 
    Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE May 03 2015 
    MannKind Looks Good For Long Term Investors Apr 29 2015 

    More From Other Websites
    U.S. panel backs approval of Sanofi combination diabetes drug May 25 2016
    Novo Nordisk IDegLira Recommended by FDA Advisory Committee May 25 2016
    4:01 am Novo Nordisk receives 16-0 vote from FDA favoring the approval of IDegLira May 25 2016
    European shares hit new 4-week high, Novo Nordisk leads May 25 2016
    European shares hit new 4-week high, Novo Nordisk leads May 25 2016
    IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee May 25 2016
    U.S. FDA panel recommends approval of Novo Nordisk diabetes drug May 24 2016
    Sanofi Is Shuffling Its Exec Roster Amid Continued Struggles May 23 2016
    FDA staff question usefulness of Sanofi diabetes drugs May 23 2016
    FDA staff question usefulness of Sanofi diabetes drugs May 23 2016
    FDA Staff Questions Usefulness of Sanofi’s Diabetes Drug Combo May 23 2016
    FDA staff question utility, trials of Novo Nordisk diabetes drug May 20 2016
    FDA staff question utility, trials of Novo Nordisk diabetes drug May 20 2016
    FDA posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination... May 20 2016
    FDA staff question utility of Novo Nordisk combo diabetes drug May 20 2016
    FDA staff question utility of Novo Nordisk combo diabetes drug May 20 2016
    Novo Nordisk A/S - Share repurchase programme May 19 2016
    Renaissance Technologies Bullish on PepsiCo (PEP) and Gold Heading Into Q2 May 18 2016
    Novo Nordisk files for regulatory approval in the US of long-acting factor IX for the treatment of... May 16 2016
    Emisphere Reports First Quarter 2016 Financial Results May 16 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)